Cargando…

Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2

Coronavirus disease 2019 (COVID-19) is a kind of viral pneumonia with an unusual outbreak in Wuhan, China, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There is currently no licensed antiviral treatment available to prevent human CoV infection. The widespread clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uzunova, Katya, Filipova, Elena, Pavlova, Velichka, Vekov, Toni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Masson SAS. 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444940/ https://www.ncbi.nlm.nih.gov/pubmed/32861965 http://dx.doi.org/10.1016/j.biopha.2020.110668

Ejemplares similares

Combining angiotensin receptor blockers with chlorthalidone or hydrochlorothiazide – which is the better alternative? A meta-analysis
por: Filipova, Elena, et al.
Publicado: (2020)

Comparative efficacy and safety of chlorthalidone and hydrochlorothiazide—meta-analysis
por: Dineva, Stela, et al.
Publicado: (2019)

Network meta-analysis of efficacy and safety of chlorthalidone and hydrochlorothiazide in hypertensive patients
por: Dineva, Stela, et al.
Publicado: (2020)

Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins
por: Filipova, Elena Pavlova, et al.
Publicado: (2015)

Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis
por: Filipova, Elena, et al.
Publicado: (2017)

Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
por: Filipova, Elena, et al.
Publicado: (2017)

A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19
por: Maciorowski, Dawid, et al.
Publicado: (2020)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

Hydroxychloroquine/lopinavir/ritonavir: Exanthema and eosinophilia: 12 case reports
Publicado: (2020)

Dexamethasone/hydroxychloroquine/lopinavir/ritonavir: Various toxicities: case report
Publicado: (2021)

Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials
por: Izcovich, Ariel, et al.
Publicado: (2022)

Hydroxychloroquine/lopinavir/ritonavir: Various side effects: 7 case reports
Publicado: (2020)

Hydroxychloroquine/lopinavir/ritonavir: Bradycardia and off-label-use: case report
Publicado: (2021)

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
por: Sheahan, Timothy P., et al.
Publicado: (2020)

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
por: Ader, Florence, et al.
Publicado: (2021)

Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel
por: Zequn, Zheng, et al.
Publicado: (2021)

Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review
por: Qomara, Windi Fresha, et al.
Publicado: (2021)

Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19
por: Echarte-Morales, Julio, et al.
Publicado: (2021)

Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients
por: Schneider, Johanna, et al.
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Guillain-Barre-syndrome and off-label-use: case report
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Lack of efficacy and off label use: 3 case reports
Publicado: (2022)

Hydroxychloroquine/lopinavir/ritonavir: Lack of efficacy following off-label use: case report
Publicado: (2022)

Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir
por: Yin, Guosheng, et al.
Publicado: (2020)

“Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers
por: Gérard, Alexandre, et al.
Publicado: (2020)

Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC–MS/MS method in human serum
por: Habler, Katharina, et al.
Publicado: (2021)

An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results
por: Ader, Florence
Publicado: (2022)

Hydroxychloroquine/lopinavir/ritonavir/tocilizumab: Lack of efficacy following off label use: case report
Publicado: (2022)

Lopinavir/ritonavir/remdesivir: Drug induced liver injury and off label use: 5 case reports
Publicado: (2020)

Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients
por: Gao, Guiju, et al.
Publicado: (2020)

Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with Moderate COVID-19, A Randomized, Double-blind Clinical Trial
por: Nekoukar, Zahra, et al.
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Acute generalised exanthematous pustulosis with erythema multiforme-like lesions: case report
Publicado: (2020)

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
por: Arabi, Yaseen M., et al.
Publicado: (2021)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis
por: Lecronier, Marie, et al.
Publicado: (2020)

Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome
por: Hraiech, Sami, et al.
Publicado: (2020)

Hydroxychloroquine/lopinavir/ritonavir/methylprednisolone: Manic episode with psychotic features during an off-label use: case report
Publicado: (2020)

Azithromycin/hydroxychloroquine/lopinavir/ritonavir: Brugada-like ECG pattern following off-label use: case report
Publicado: (2021)

Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019
por: Kim, Ji-Won, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h8blrg8fh8irm7k572rfjji66u